The associations between proprotein convertase subtilisin/kexin type 9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels: a meta-analysis

Cai, Gaojun; Zhang, Bifeng; Shi, Ganwei; Weng, Weijin; Ma, Chunyan; Song, Yanbin; Zhang, Ji

doi:10.1186/s12944-015-0154-7

Lipids in Health and Disease

Table 2 Characteristics of individual studies included in the meta-analysis of PCSK9 E670G polymorphism and lipid levels

From: The associations between proprotein convertase subtilisin/kexin type 9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels: a meta-analysis

First author	Year	Country	Ethnicity	Type of study	Subpopulation	Genotype	Number (n)	TC (mmol/l)		TG (mmol/l)		HDL-C (mmol/l)		LDL-C (mmol/l)		Genotyping method
First author	Year	Country	Ethnicity	Type of study	Subpopulation	Genotype	Number (n)	M	SD	M	SD	M	SD	M	SD	Genotyping method
Chen SN 1 [13]	2005	American	Mixed	Cohort	LCAS population	AA	324	5.69	0.62	1.83	0.64	1.14	0.29	3.72	0.51	Allelic discrimination assays
						AG + GG	48	5.82	0.66	1.66	0.63	1.16	0.31	3.89	0.57	Allelic discrimination assays
Chen SN 2 [13]	2005	American	Caucasian	Cohort	TexGen population	AA	292	NA	NA	NA	NA	NA	NA	2.28	0.65	Allelic discrimination assays
						AG + GG	27	NA	NA	NA	NA	NA	NA	2.43	0.55	Allelic discrimination assays
Evans D 1 [14]	2006	Germany	Caucasian	Cohort	Male group	AA	190	6.05	1.4	1.39	0.45	1.16	0.31	4.29	1.34	PCR-RFLP
						AG + GG	26	6.57	1.48	1.55	0.44	1.2	0.29	4.65	1.37
Evans D 2 [14]	2006	Germany	Caucasian	Cohort	Female group	AA	210	6.83	1.45	1.32	0.45	1.55	0.44	4.65	1.45	PCR-RFLP
						AG + GG	18	6.65	1.47	1.22	0.23	1.58	0.52	4.5	1.37
Scartezini M [15]	2007	UK	Caucasian	Cohort	NPHSII men	AA	930	5.73	0.99	NA	NA	0.81	0.24	3.98	0.94	PCR-RFLP
						AG + GG	135	5.65	0.96	NA	NA	0.83	0.26	3.92	0.94
Polisecki E 1 [17]	2008	American	Caucasian	Cohort	Male group	AA	2455	5.25	0.03	NA	NA	NA	NA	3.47	0.03	Taqman
						AG + GG	165	5.26	0.06	NA	NA	NA	NA	3.47	0.06
Polisecki E 2 [17]	2008	American	Caucasian	Cohort	Female group	AA	2638	5.71	1.73	NA	NA	NA	NA	3.73	1.59	Taqman
						AG + GG	158	5.85	0.95	NA	NA	NA	NA	3.84	0.84
Hsu LA 1 [10]	2009	Taiwan	Asian	C-C	CAD group	AA	541	5.14	0.96	1.59	1.3	1.42	0.37	3.02	0.85	PCR-RFLP
						AG	73	4.95	0.96	1.72	1.53	1.44	0.36	2.78	0.82
Hsu LA 2 [10]	2009	Taiwan	Asian	C-C	Control group	AA	182	5.29	1.31	2.32	2.07	1.04	0.27	3.25	1.17	PCR-RFLP
						AG	20	5.28	0.74	2.48	1.4	1.07	0.33	3.41	0.6
Norata GD 1 [18]	2010	Italy	Caucasian	Cohort	PLIC study	AA	1466	5.71	0.98	1.2	0.79	1.42	0.38	3.74	0.9	Taqman
						AG + GG	75	5.99	1.2	1.16	0.58	1.45	0.35	4.01	1.07
Norata GD 2 [18]	2010	Italy	Caucasian	Cohort	Ventimiglia study	AA	728	4.76	0.99	NA	NA	NA	NA	3.02	0.86	Taqman
						AG + GG	48	4.89	0.98	NA	NA	NA	NA	3.23	0.87
Zeng J [19]	2011	China	Asian	C-C	CAD group	AA	167	3.73	0.8	1.5	0.59	1.26	0.38	2.16	0.73	PCR-RFLP
						AG + GG	45	4.25	1.38	1.87	1.16	1.26	0.41	2.58	1.08
Meng YH [7]	2011	China	Asian	C-C	CAD group	AA	146	4.41	0.72	0.99	0.62	1.48	0.51	2.22	0.63	PCR-RFLP
						AG	19	4.63	1.21	1.17	0.97	0.98	0.84	3.02	0.97
Aung LHH 1 [21]	2013	China	Asian	Cohort	non-drinker group	AA	744	4.59	0.99	1.23	0.92	1.82	0.49	2.55	0.82	PCR-RFLP
						AG	41	5.01	1.25	1.09	0.78	1.86	0.51	2.68	0.86
Aung LHH 2 [21]	2013	China	Asian	Cohort	Drinker group	AA	543	4.84	1.07	1.02	0.73	1.74	0.44	2.94	0.81	PCR-RFLP
						AG	24	4.55	0.64	1.1	0.58	1.63	0.5	2.69	0.44
Mayne J [20]	2013	Canada	Caucasian	Cohort	African Canadian population	AA	192	5.56	1.14	1.59	0.77	1.2	0.4	3.64	1.01	PCR + full exonic sequencing
						AG	15	5.11	1.12	1.27	0.48	1.1	0.3	3.45	1.11	PCR + full exonic sequencing
Slimani A 1 [8]	2014	Tunisian	African	C-C	CAD group	AA	148	NA	NA	1.69	0.86	1	0.36	NA	NA	PCR-RFLP
						AG + GG	44	NA	NA	1.97	0.96	1.03	0.16	NA	NA
Slimani A 2 [8]	2014	Tunisian	African	C-C	IS group	AA	90	NA	NA	1.58	0.75	1.35	0.4	NA	NA	PCR-RFLP
						AG + GG	24	NA	NA	1.47	0.58	1.04	0.19	NA	NA
Anderson JM 1 [22]	2014	Brazil	Caucasian	C-C	HC group	AA	91	7.21	0.96	1.87	0.8	1.45	0.36	4.89	0.88	Taqman
						AG + GG	37	7.4	0.96	1.81	0.76	1.5	0.31	4.94	0.8
Anderson JM 2 [22]	2014	Brazil	Caucasian	C-C	NL group	AA	131	4.47	0.47	0.91	0.32	1.53	0.36	2.53	0.47	Taqman
						AG + GG	40	4.5	0.49	0.95	0.3	1.47	0.26	2.59	0.47
Zhang L 1 [23]	2014	China	Asian	C-C	CAD group	AA	291	4.07	1.16	1.82	0.79	1.37	0.16	2.29	0.77	PCR-RFLP
						AG + GG	125	4.49	1.31	1.87	1.09	1.31	0.25	2.5	0.74
Zhang L 2 [23]	2014	China	Asian	C-C	Control group	AA	212	4.67	0.62	1.45	1.16	1.49	0.21	2.67	0.81	PCR-RFLP
						AG	45	4.53	0.33	1.37	0.88	1.4	0.21	2.63	0.8
Jeenduang N 1 [24]	2015	Thai	Asian	Cohort	Male group	AA	132	5.54	1.3	1.46	0.84	1.32	0.35	3.66	1.13	PCR-RFLP
						AG	3	5.82	2.25	1.4	0.92	1.19	0.21	4	2.06
Jeenduang N 2 [24]	2015	Thai	Asian	Cohort	Female group	AA	347	5.54	1.22	1.22	0.74	1.45	0.34	3.62	0.95	PCR-RFLP
						AG	13	5.99	0.94	1.01	0.35	1.49	0.23	4.04	0.94
Mo YQ [26]	2015	China	Asian	C-C	CAD group	AA	87	4.48	0.81	0.97	0.58	1.49	0.47	2.12	0.72	DNA sequencing
						AG	13	4.56	0.97	1.05	0.89	0.97	0.73	3.01	0.83

C-C case–control, CAD coronary artery disease, IS ischemic stroke, NA not available, HC hypercholesterolemics, NL normolipidemics, UK United Kingdom, PCR-RFLP polymerase chain reaction- restriction fragment length polymorphism

Back to article page

ISSN: 1476-511X

Contact us

General enquiries: journalsubmissions@springernature.com